PRMT5, which is the predominant type II methyltransferase-targeting arginine methylation, is upregulated in a variety of hematological malignancies and its overexpression is associated with tumor aggressiveness and poor overall survival [17–21]. Here, PRMT5 is linked to neoplasm.